Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs, By Indication, By Route of Administration, By Distribution Channel, and By Region

Description

Angiotensin Converting Enzymes (ACE) Inhibitors Market is estimated to be valued at USD 9,000.3 Mn in 2025 and is expected to reach USD 13,179.7 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.6% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 9,000.3 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	5.60%	2032 Value Projection:	USD 13,179.7 Mn

Angiotensin converting enzymes (ACE) inhibitors are a type of medication used primarily in the treatment of high blood pressure and heart failure. They work by blocking the action of a hormone called angiotensin II. Angiotensin II causes blood vessels to constrict and promotes the release of another hormone called aldosterone, which leads to water and salt retention in the body. By inhibiting the production of angiotensin II, ACE inhibitors help to relax and widen the blood vessels, reduce the amount of water retained by the body, and therefore lower blood pressure. Commonly prescribed ACE inhibitors include lisinopril, enalapril, and ramipril. Side effects can include dry cough, dizziness, and kidney problems. It is important for individuals taking ACE inhibitors to have regular check-ups to monitor their kidney function and potassium levels. ACE inhibitors play a pivotal role in mitigating the effects of angiotensin II, aiding in the relaxation and widening of blood vessels while regulating fluid retention, thus contributing significantly to blood pressure reduction.

Market Dynamics

The global angiotensin converting enzymes (ACE) inhibitors market's growth is driven by the high prevalence of hypertension and heart disease globally. The body produces four distinct forms of the hormone angiotensin (an-gee-oh-ten-sin; the types' names are Roman numerals). Angiotensin I is converted to angiotensin II by ACE, which has a variety of bodily consequences. ACE inhibitors are often recommended, particularly for cardiovascular diseases and high blood pressure. An ACE inhibitor was given to over 12.9 million Medicare Part D participants in 2019 (or roughly 27% of all beneficiaries with Part D coverage). It is true that ACE inhibitors can cause negative effects. Most of them are mild, but a few are dangerous and require emergency medical attention.

Key features of the study

This report provides in-depth analysis of the global angiotensin converting enzymes (ACE) inhibitors market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global angiotensin converting enzymes (ACE) inhibitors market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Novartis AG, Pfizer Inc., Merck & Co., AstraZeneca, Sanofi, Boehringer Ingelheim, GlaxoSmithKline, Lupin Limited, Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Mylan and Other Prominent Players.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global angiotensin converting enzymes (ACE) inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global angiotensin converting enzymes (ACE) inhibitors market.

Market Segmentation

By Drugs
- Benazepril
- Perindopril
- Trandfolapril
- Captopril
- Enalapril
- Lisinopril
- Others (Ramipril, etc.)
By Indication
- Hypertension
- Coronary Artery Disease
- Heart Failure
- Chronic Kidney Disease
- Scleroderma
- Others (Migraine, etc.)
By Route of Administration
- Oral
- Injectable
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Top companies in Global Angiotensin Converting Enzymes (ACE) Inhibitors Market
- Novartis AG
- Pfizer Inc.
- Merck & Co.
- AstraZeneca
- Sanofi
- Boehringer Ingelheim
- GlaxoSmithKline
- Lupin Limited
- Torrent Pharmaceuticals Ltd.
- Reddy's Laboratories Ltd.
- Mylan
- Other Prominent Players

Product Code: CMI2746

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Drugs
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Indication
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Route of Administration
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Distribution Channel
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
  - Rising prevalence of hypertension
  - Growing Research and Development Activities
  - Increasing Awareness of Cardiovascular Health
- Restraints
  - Patent Expirations
  - Side Effects and Safety Concerns
  - Side Effects and Safety Concerns
- Opportunities
Increasing Awareness of Cardiovascular Health
Personalized medicine
Combination therapies
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Benazepril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Perindopril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Trandfolapril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Captopril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Enalapril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Lisinopril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Others (Ramipril, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Indication, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Hypertension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn )
Coronary Artery Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn )
Heart Failure
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn )
Chronic Kidney Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn )
Scleroderma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)
Others (Migraine, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)

6. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Route of Administration, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Distribution Channel, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Region, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 -2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (USD Mn)
  - GCC
  - Israel
  - North Africa
  - Central Africa
  - Rest of Middle East & Africa

9. Competitive Landscape

Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Merck & Co.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Lupin Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Torrent Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Mylan
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Analyst Views

10. Section

Research Methodology
About us